



FROM POLLUTANT TO PILL: CAN MICROPLASTICS IN FOOD BE RECLAIMED FOR PARACETAMOL PRODUCTION

Medhavi Sudarshan

Assistant Professor, Department of Zoology, Jagat Narain Lal College, Khagaul

Patliputra University, Patna, Bihar, India

Corresponding Author Email ID: medhavisudarshan@gmail.com

ABSTRACT

The presence of microplastics in food has emerged as a major public health issue. At the same time, waste plastic may now be turned into valuable medications like paracetamol thanks to synthetic biology. With an emphasis on technological viability, existing obstacles, and wider ramifications for pharmaceutical innovation and environmental health, this mini-review investigates whether foodborne microplastics may be a sustainable feedstock for pharmaceutical manufacturing.

Keywords: Microplastic, Synthetic biology, Paracetamol, Technology, Health

INTRODUCTION

According to Smith et al. (2018), microplastics, which are plastic particles smaller than 5 mm, are now present in almost every food item in the world, including fruits, vegetables, seafood, salt, and drinking water [1]. These particles might endanger both ecological equilibrium and human health. The capacity of microbial biotechnology to transform plastic garbage into necessary medications like paracetamol is an unanticipated intersection of pharmaceutical innovation and environmental research [2]. This raises the intriguing question of whether the contaminants found in our food may be turned into medicinal remedies.

THE THREAT OF MICROPLASTICS IN THE FOOD CHAIN

Microplastics are formed when bigger plastics degrade and enter the food chain through soil, water, air, and processing materials [3]. According to research, individuals may consume millions of microplastic particles each year, however their physiological implications are still being studied [4]. Chemical additions like phthalates and bisphenol A increase its toxicity. Despite growing concern, present recycling methods cannot manage particles on such small dimensions, especially when incorporated in biological components.

BREAKTHROUGH: PLASTIC TO PARACETAMOL VIA SYNTHETIC BIOLOGY

Recent developments have demonstrated the enzymatic breakdown of polyethylene terephthalate (PET), a popular plastic used in bottles, into its monomers, ethylene glycol and terephthalic acid (TPA) [2, 5]. Researchers expanded on this by genetically modifying *Escherichia coli* to biosynthesise paracetamol and metabolise TPA [2]. Green chemistry and the circular bioeconomy are promoted by this biosynthetic approach, which substitutes cleaner, more energy-efficient processes for hazardous chemical ones.

CAN FOODBORNE MICROPLASTICS SERVE AS FEEDSTOCK

Mostly composed of PET or related polymers, foodborne microplastics may be vulnerable to enzymatic and microbial degradation [5, 6]. However, extraction and homogeneity are challenging due to their low concentration and diversity [4, 7]. Microbial cultures used in bioproduction are at risk from contaminants like heavy metals and organic toxins [3, 8]. It is difficult and expensive to isolate and sterilise foodborne microplastics for use in pharmaceuticals [9, 10]. Low yield, hazardous additives, polymer heterogeneity, and food safety issues are some of the difficulties associated with using foodborne microplastics as feedstock for the production of paracetamol [7, 8]. The possibility of employing foodborne microplastics as a feedstock for pharmaceutical manufacturing is still of interest in spite of these obstacles [11, 12].

IMPLICATIONS FOR CIRCULAR BIOECONOMY

Pharmaceutical biosynthesis and plastic waste valorisation are closely aligned with the goals of a circular bioeconomy, which allows environmental pollutants to be converted into necessary pharmaceuticals—a dual solution to global challenges [10]. This environmentally friendly method lessens reliance on dangerous chemicals and petrochemical feedstocks that are frequently used to produce paracetamol [13]. Rapid reprogrammability provided by bio-based platforms enables the redesign of microbial chassis for the production of additional aromatic drugs from PET waste [14]. Using plastic-derived substrates, similar engineered microbes can be repurposed for multiple therapeutic targets, marking a paradigm shift in green pharmaceutical manufacturing [15, 16].

CHALLENGES, FUTURE PROSPECTS, SCIENTIFIC OUTLOOK, STRATEGIC POTENTIAL

Through modular engineering of catabolic and biosynthetic pathways, advanced synthetic biology provides the possibility of upcycling complex or impure plastic sources, allowing for the microbial degradation of heterogeneous polymers [6]. Plastic-to-drug bio refineries can help address the twin crises of environmental waste and medicine scarcity, which is especially pertinent in areas with plastic pollution and pharmaceutical shortages [2]. Nevertheless, the pathway has drawbacks like low titers, cofactor imbalances, and by-product inhibition, which necessitate co-optimization of flux balance and redox and are typical metabolic constraints in engineered microbes [12]. With programmable control over gene expression and network dynamics, advanced metabolic engineering, CRISPR-based genome editing, and AI-driven pathway optimisation can improve yields [17-20].

In order to overcome metabolic bottlenecks, increase pathway modularity, and prevent intracellular toxicity, future research may concentrate on microbial consortia or cell-free enzymatic cascades [21, 22]. Because of biosafety and environmental containment concerns, it is imperative to address concerns regarding genetically modified organisms (GMOs) and bioreactor contamination, particularly in large-scale production settings [23].

These tactics could be especially revolutionary in low-income, resource-constrained environments where plastic pollution is a major problem and traditional supply chains are unable to meet pharmaceutical demands.

CONCLUSION

The technology of turning foodborne microplastics into paracetamol has the potential to address global issues such as pollution and healthcare access. Synthetic biology offers a new perspective on pollution, viewing it as a raw material for healing rather than a threat. The microbial conversion of plastic waste into paracetamol exemplifies the power of synthetic biology in addressing these issues. As the world faces plastic accumulation and drug shortages, these innovations may redefine how medicines are manufactured sustainably, affordably, and circularly. The microbial conversion of clean PET into paracetamol sets the precedent for reframing threats as opportunities, and if scientific and regulatory challenges are overcome, foodborne microplastics may shift from contamination to cure.

CONFLICT OF INTEREST

No

REFERENCES

- [1]. M. Smith, D. C. Love, C. M. Rochman, and R. A. Neff, "Microplastics in Seafood and the Implications for Human Health," (in eng), *Curr Environ Health Rep*, vol. 5, no. 3, pp. 375-386, Sep 2018, doi: 10.1007/s40572-018-0206-z.
- [2]. N. W. Johnson et al., "A biocompatible Lossen rearrangement in *Escherichia coli*," (in eng), *Nat Chem*, Jun 23 2025, doi: 10.1038/s41557-025-01845-5.
- [3]. S. L. Wright and F. J. Kelly, "Plastic and Human Health: A Micro Issue?," (in eng), *Environ Sci Technol*, vol. 51, no. 12, pp. 6634-6647, Jun 20 2017, doi: 10.1021/acs.est.7b00423.
- [4]. K. D. Cox, G. A. Covernton, H. L. Davies, J. F. Dower, F. Juanes, and S. E. Dudas, "Human Consumption of Microplastics," (in eng), *Environ Sci Technol*, vol. 53, no. 12, pp. 7068-7074, Jun 18 2019, doi: 10.1021/acs.est.9b01517.
- [5]. S. Yoshida et al., "A bacterium that degrades and assimilates poly(ethylene terephthalate)," (in eng), *Science*, vol. 351, no. 6278, pp. 1196-9, Mar 11 2016, doi: 10.1126/science.aad6359.
- [6]. T. Tiso et al., "Towards bio-upcycling of polyethylene terephthalate," (in eng), *Metab Eng*, vol. 66, pp. 167-178, Jul 2021, doi: 10.1016/j.ymben.2021.03.011.
- [7]. L. G. A. Barboza et al., "Microplastics in wild fish from North East Atlantic Ocean and its potential for causing neurotoxic effects, lipid oxidative damage, and human health risks associated with

- ingestion exposure," (in eng), Sci Total Environ, vol. 717, p. 134625, May 15 2020, doi: 10.1016/j.scitotenv.2019.134625.
- [8]. J. C. Prata, J. P. da Costa, I. Lopes, A. C. Duarte, and T. Rocha-Santos, "Environmental exposure to microplastics: An overview on possible human health effects," (in eng), Sci Total Environ, vol. 702, p. 134455, Feb 01 2020, doi: 10.1016/j.scitotenv.2019.134455.
- [9]. J. H. Kwon et al., "Microplastics in Food: A Review on Analytical Methods and Challenges," (in eng), Int J Environ Res Public Health, vol. 17, no. 18, Sep 15 2020, doi: 10.3390/ijerph17186710.
- [10]. H. Y. Leong et al., "Waste biorefinery towards a sustainable circular bioeconomy: a solution to global issues," (in eng), Biotechnol Biofuels, vol. 14, no. 1, p. 87, Apr 07 2021, doi: 10.1186/s13068-021-01939-5.
- [11]. U. Anand et al., "Biotechnological methods to remove microplastics: a review," (in eng), Environ Chem Lett, vol. 21, no. 3, pp. 1787-1810, 2023, doi: 10.1007/s10311-022-01552-4.
- [12]. G. Wu, Q. Yan, J. A. Jones, Y. J. Tang, S. S. Fong, and M. A. G. Koffas, "Metabolic Burden: Cornerstones in Synthetic Biology and Metabolic Engineering Applications," (in eng), Trends Biotechnol, vol. 34, no. 8, pp. 652-664, Aug 2016, doi: 10.1016/j.tibtech.2016.02.010.
- [13]. F. Hou, D. Feng, M. Xian, and W. Huang, "Biosynthesis and Whole-Cell Catalytic Production of 2-Acetamidophenol in," (in eng), J Agric Food Chem, vol. 70, no. 1, pp. 238-246, Jan 12 2022, doi: 10.1021/acs.jafc.1c06910.
- [14]. T. Bao, Qian, Y., Xin, Y., Collins, J. J., & Lu, T., "Engineering microbial division of labor for plastic upcycling," doi: <https://doi.org/10.1038/s41467-023-40777-x>.
- [15]. H. Chen, K. Wan, Y. Zhang, and Y. Wang, "Waste to Wealth: Chemical Recycling and Chemical Upcycling of Waste Plastics for a Great Future," (in eng), ChemSusChem, vol. 14, no. 19, pp. 4123-4136, Oct 05 2021, doi: 10.1002/cssc.202100652.
- [16]. P. W. Shuai Yue , Bingnan Yu , Tao Zhang , Zhiyong Zhao , Yi Li , Sihui Zhan, "From Plastic Waste to Treasure: Selective Upcycling through Catalytic Technologies,"
doi: <https://arxiv.org/abs/2309.08354> .
- [17]. S. Cho, J. Shin, and B. K. Cho, "Applications of CRISPR/Cas System to Bacterial Metabolic Engineering," (in eng), Int J Mol Sci, vol. 19, no. 4, Apr 05 2018, doi: 10.3390/ijms19041089.
- [18]. L. S. Qi et al., "Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression," (in eng), Cell, vol. 152, no. 5, pp. 1173-83, Feb 28 2013, doi: 10.1016/j.cell.2013.02.022.
- [19]. J. Nielsen and J. D. Keasling, "Engineering Cellular Metabolism," (in eng), Cell, vol. 164, no. 6, pp. 1185-1197, Mar 10 2016, doi: 10.1016/j.cell.2016.02.004.
- [20]. Mirchandani, Y. Khandhediya, and K. Chauhan, "Review on Advancement of AI in Synthetic Biology," (in eng), Methods Mol Biol, vol. 2952, pp. 483-490, 2025, doi: 10.1007/978-1-0716-4690-8_26.

- [21]. G. W. Roell, J. Zha, R. R. Carr, M. A. Koffas, S. S. Fong, and Y. J. Tang, "Engineering microbial consortia by division of labor," (in eng), *Microb Cell Fact*, vol. 18, no. 1, p. 35, Feb 08 2019, doi: 10.1186/s12934-019-1083-3.
- [22]. H. J. Lim and D. M. Kim, "Cell-Free Metabolic Engineering: Recent Developments and Future Prospects," (in eng), *Methods Protoc*, vol. 2, no. 2, Apr 30 2019, doi: 10.3390/mps2020033.
- [23]. B. Junker et al., "Sustainable reduction of bioreactor contamination in an industrial fermentation pilot plant," (in eng), *J Biosci Bioeng*, vol. 102, no. 4, pp. 251-68, Oct 2006, doi: 10.1263/jbb.102.251.

Cite this Article

Medhavi Sudarshan, "From Pollutant to Pill: Can Microplastics in Food Be Reclaimed for Paracetamol Production", *International Journal of Scientific Research in Modern Science and Technology (IJSRMST)*, ISSN: 2583-7605 (Online), Volume 4, Issue 7, pp. 64-68, July 2025.

Journal URL: <https://ijrmst.com/>

DOI: <https://doi.org/10.59828/ijrmst.v4i7.344>.



This work is licensed under a [Creative Commons Attribution-NonCommercial 4.0 International License](https://creativecommons.org/licenses/by-nc/4.0/).